Is there a remote chance that Neu and Acad decide to do some bartering over the new indications? For example, what if Neu agreed to license development of PWS to Acad (after clearing the protocol discussion with FDA in Q3) in exchange for certainty about Acad agreeing that certain new indications Neu wants to pursue are exempt from non-compete?
Neu and Acad have had a very productive relationship to date and established the precedent deal of ring-fencing 4 indications for Neu and licensing 2 to Acad. Is this then a type of deal that could be extended? Acad gets PWS licensing as a more relevant and complementary asset to its portfolio but Neu gets 2,3 or 4 extra indications ring-fenced to generate a saleable asset (with revenue streams from Acad thrown in?)
Just a Sunday musing..
Neuren Media and Analyst Coverage, page-1204
-
- There are more pages in this discussion • 47 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.45 |
Change
-0.070(0.34%) |
Mkt cap ! $2.613B | |||
| Open | High | Low | Value | Volume |
| $20.60 | $20.77 | $20.32 | $3.866M | 188.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 237 | $20.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.49 | 1026 | 2 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |